Adding Retifanlimab To Chemotherapy Provides OS Benefit over Chemotherapy In First-Line Treatment of Patients with Advanced Squamous Anal Cancer By Ogkologos - May 18, 2026 163 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival analysis in the POD1UM-303/InterAACT-2 study Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric or GEJ Adenocarcinoma Advancing Childhood Cancer Research: A Conversation with Dr. Brigitte Widemann Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML MOST POPULAR News digest – Genetic links to male breast cancer, bowel cancer... August 15, 2020 Liquid Biopsy Detects Brain Cancer and Early-Stage Kidney Cancer July 23, 2020 COVID-19 Vaccine Myth Busters January 28, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Selumetinib April 30, 2021 Load more HOT NEWS Study Improves the Quality of Biopsy Specimens for Cancer Research Complete Cancer Prevalence in Europe in 2020 Reveals an Increased Proportion... Cancer Won’t Wait: “I prayed she would see her daughter start... Adjuvant Pembrolizumab Continues to Demonstrate a Clinically Meaningful DMFS Benefit in...
